Pharmacological characterization of nalorphine, a kappa 3 analgesic

D Paul, CG Pick, LA Tive and GW Pasternak

Cotzias Laboratory of Neuro-Oncology, Cornell University Medical College, New York, New York.

Nalorphine is an unusual opiate. Whereas low doses of nalorphine antagonize morphine analgesia, higher nalorphine doses are analgesic, with ED50 values (95% CL) of 13.4 (11.5, 15.8) mg/kg in the writhing and 39.5 (26.6, 60.1) mg/kg in the tail-flick assay. Although nalorphine analgesia is sensitive to naloxone, implying an opioid mechanism, neither beta-funaltrexamine, naltrindole nor nor- binaltorphomine antagonized nalorphine analgesia in the tail-flick assay at doses which reversed equianalgesic doses of their respective selective agonists. Nalorphine and the kappa 3 opiate naloxone benzoylhydrazone demonstrated analgesic cross-tolerance regardless of whether the mice were treated chronically with either nalorphine or naloxone benzoylhydrazone. Animals tolerant to nalorphine were not tolerant to either morphine or U50,488H (trans-3,4-dichloro-N-methyl-N- [2-(pyrrolindinyl)-cyclohexyl]- benzeneacetamide). Furthermore, nalorphine retained its analgesic potency in animals tolerant to U50,488H. Nalorphine exerts its analgesia predominantly through supraspinal mechanisms. Against systemically administered nalorphine, the opiate antagonist WIN44,441 ([2,6,11S-(-)-1-cyclopentyl-5- (1,2,3,4,5,6-hexahydro-8-hydroxy-3,6, 11-trimethyl-2,6-methano-e- benazocine-11-yl)-3-pentanone methylsulfonate) reversed nalorphine analgesia 1500-fold more potently when administered i.c.v. (ID50, 0.1 ng) than when given intrathecally (ID50,159 ng). Together these results indicate that nalorphine analgesia in the tail-flick assay does not involve mu, delta or the U50,488H-sensitive kappa 1 receptor and strongly suggest a role for supraspinal kappa 3 receptors.

Volume 257, Issue 1, pp. 1-7, 04/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Temsamani, C. Bonnafous, C. Rousselle, Y. Fraisse, P. Clair, L.-A. Granier, A. R. Rees, M. Kaczorek, and J.-M. Scherrmann Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 712 - 719. [Abstract] [Full Text] [PDF]

				J. Mei and G. W. Pasternak sigma 1 Receptor Modulation of Opioid Analgesia in the Mouse J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1070 - 1074. [Abstract] [Full Text] [PDF]

				T. Nanovskaya, S. Deshmukh, M. Brooks, and M. S. Ahmed Transplacental Transfer and Metabolism of Buprenorphine J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 26 - 33. [Abstract] [Full Text] [PDF]

				A. E. Remmers, M. J. Clark, A. Mansour, H. Akil, J. H. Woods, and F. Medzihradsky Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 827 - 833. [Abstract] [Full Text]